Introduction it is cle{wly desirflble to develop Iflbomt01y tests thflt pl o ovide fill indication of the pe'i017llflnce of tflblets in1JJfln, tbe so-called in vitro-ill vivo cOln/fItion (lVlVQ ol o ,oelatiombip (Iv/VR) (1 --1). Mflny flttempts hflve been mflde to estflb/isb tbese ,"elfltionsbipSf01" fI v{wiety of {ho/tgs find fimlllllatio17S

Solubility of the Drug Substance
The drug su bsta nce has poor aqucous solubility at low and moderate pr 1 and needs to be modified to makc it more solubl e ( figure I). , .. This degree of solubility classifi es the drug as having 'Low Solubi li ty' as defin ed in the SUPAC guidelines recentl y produced by the FDA.
Development of a Discriminating Dissolution Test
For tabl ets containing 200 mg drug substance, a dissolution test was developed based on the USP ApparanlS 2 paddle method with a weakly buffered (figU1"e I) . Instead, an alternative test method was developed using the USP 4 Aow-through apparanls, which differs from the USP Apparatus 2 in having a much smaller dissolution cell (approx. 16mL compared to 900 mL) and fresh dissolution medium constantly contacti ng the dosage form thus maintaining 'sink' conditions throughout the test.
TIme (mlns)
The batch of standard tablets (batch 00 I) was used to assess the effects of several test variables on the dissolution ratc, the most important one being pH (fi[JIt1'e 4). ., This USP Apparatus 4 test provided excellent discrimination between tablets contai ning modified and unlllodified drug substance (figure 5) and also discrilllinated well between the clinical batches that had low bioavailability (fig"re 6 (fig"re 7) .
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Although not linear, there is a clear relationship between % released after 30 mjnutes and bioavailabi lity, all four batches shmving the correct rank order. From figure 7, a specification limit of> 55 % released after 30 minutes was set for acceptable release of drug from the tablets. This corresponded to tablets that gave 90% relative bioavailability in man.
., Having developed a discrimimting dissolution test that dCIllOltstnlted a gocx:I in vitro-in vivo relationship, it was used to look at critical parameters for the tablet manufacturing process, such as mill speed and compression force. Figure 8 shows the effect of mill speed 011 dissolution rate, indicating that a mill speed of at least 4500 is required to produce ta blets with an acceptable dissolution rate of > 55% after 30 minutes. From such studies, the 'operating window' fOr the entire process at the manufactwing scale is being defin ed.
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Conclusion
A dissolu tio n test that shows an in vi tro-in vivo correlatio n has been developed usin g the USP Apparatus 4 fl ow-through dissoluti on test. T his discriminating test has been a powerful tool in dennin g th e 'operati ng window' for th e process and has obviated the need to conduct expensive and ti me consum ing bi oeqll iva lence studi es every ti me a process change has been conducted.
